The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023
Published: Nov-2013 | Format: PDF | GMR Data | Number of pages: 243 | Code: MRS - 858
GMR Data forecast that the global cancer drugs and treatments market will reach $143.7bn by 2023. GMR Datas latest report 'The Cancer Drugs & Treatments Market Data, Analysis & Forecasts to 2023 explains just how this market will experience growth over the medium and long term. The report also highlights forecast for the next 5 and 10 years, so that you and your company can make specific long term plans. Dont let your competitors get the head-start on you, order this report today.
- Have you seen the recent news on Cancer Drugs
- Mercks new cancer drug kept more than 4 of 5 melanoma patients alive for a year
- Biopharma Alliances will be needed For Cancer Drugs in the cost conscious future Forbes
- EU approval for Bayers prostate cancer drug
- Sanofi ditches late-stage bone marrow cancer drug
The Anti-cancer treatment market is already worth $77.4bn (GMR Data) and continues to be one of the largest and fastest growing areas for new drug development can you afford not to be involved Should you and your company be capturing a greater market share
Essential facts examined in this report
- Across 2013, 15 new molecular entities were approved by the FDA; out of which seven were for Oncology.
- Currently targeted therapies dominate the oncology pipeline, followed by chemotherapy.
- Immunotherapy drugs are gaining increasing amounts of attention due to fewer expected side effects.
- Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this new GMR Data report.
Discover exactly what the industry leaders are doing TODAY -
Within GMR Datas 'The Cancer Drugs & Treatments Market Data, Analysis & Forecasts to 2023 we analyse the key cancer drugs and treatments in the market currently and how they will perform across the next decade.
Our study focuses on the individual revenues of the top 25 anti-cancer agents. With variable patents and the threat of generics, how will these key cancer drugs fare across the next decade ONLY THIS UNIQUE REPORT WILL TELL YOU
PLUS In-depth country analysis Discover which countries and regions will drive the oncology drugs market to 2023
The US spent $322bn on healthcare in 2011, GMR Data estimate that the US spent $31.8bn in the oncology market in 2012, capturing 40.5% of the market. 2nd to the US was Japan; spending $8.9bn in 2012, capturing 11.2%. The European mainstays of the pharmaceutical sector; the UK, Germany, France, Spain & Italy equated to 25% of the global oncology market in 2012.
But how will these countrys markets develop This report will tell you TODAY
Exclusive Industry sourced information, not available anywhere else
- As well as primary and secondary research sources, GMR Data have interviewed leading cancer specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field This information is not available anywhere else.
- This GMR Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Cancer Drugs. This report will arm you with all you and your company require to develop, price, launch and market a cancer drug.
- With over 240+ pages, and over 270+ charts, tables and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.
Table of Content
Chapter 1 Executive Summary1.1 Cancer Drugs Market Review - How will the cancer drugs market grow to 2023? What is it worth today? Why?
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
Chapter 2 Types of Cancer; Causes, symptoms and global prevalance of the key cancers affecting the worlds population
2.1 Blood Cancer Types and Symptoms
2.1.2 Blood Cancer- Global Market
2.1.3 Blood Cancer- Causes and Risk Factors
2.2 Bone Cancer Types and Symptoms
2.2.1 Bone Cancer- Global Market
2.2.2 Bone Cancer Causes and Risk Factors
2.3 Brain Cancer Types and Symptoms
2.3.1 Brain Cancer Market- Global
2.3.2 Brain Cancer- Causes and Risk Factors
2.4 Breast Cancer Types and Symptoms
2.4.1 Breast Cancer Market- Global
2.4.2 Breast Cancer Causes and Risk factors
2.5 Digestive/ Gastrointestinal Cancer Types and Symptoms
2.5.1 Gastrointestinal Cancer Market- Global
2.5.2 Gastrointestinal Cancer- Causes and Risk Factors
2.6 Endocrine Cancers Types and Symptoms
2.6.1 Endocrine Cancer Market- Global
2.6.2 Endocrine Cancer- Causes and Risk Factors
2.7 Eye Cancer Types and Symptoms
2.7.1 Eye Cancer Market- Global
2.7.2 Eye Cancer Causes and Risk Factors
2.8 Genitourinary Cancers Types & Symptoms
2.8.1 Genitourinary Cancer Market Global
2.8.2 Genitourinary Cancers - Causes and Risk Factors
2.9 Gynaecologic Cancers Types & Symptoms
2.9.1 Gynaecologic Cancer Market Global
2.9.2 Gynaecologic Cancers - Causes and Risk Factors
2.10 Head & Neck Cancers Types & Symptoms
2.10.1 Head and Neck Cancer Market Global
2.10.2 Head and Neck Cancer - Causes and Risk Factors
2.11 Respiratory/Lung Cancers Types & Symptoms
2.11.1 Respiratory Cancer Market Global
2.11.2 Respiratory Cancer - Causes and Risk Factors
2.12 Skin Cancers Types & Symptoms
2.12.1 Skin Cancer Global Market
2.12.2 Skin Cancer - Causes and Risk Factors
2.13 Worldwide Cancer Facts and Statistics
2.13.1 Cancer Incidence Facts & Statistics
2.13.2 Cancer Mortality and Survival Facts & Statistics
Chapter 3 Cancer; Causes & Effects - Which factors effect the causes of cancers, globally.
3.13 Genetic Causes
3.14 Tobacco & Smoking
3.15 Physical Activities and Eating Habits
3.16 Viral Infections
3.17 Bacterial Infections
Chapter 4 Cancer Treatment Types & Side Effects
4.1.1 Potential Side effects of Surgery
4.2 Chemotherapy - How will the mainstay of cancer treatment fair Vs. newer types of cancer treatment?
4.2.1 Major Side effects of Chemotherapy
4.3 Radiation Therapy
4.3.1 Major Side effects of Radiation Therapy
4.4 Targeted Therapy - Precision drugs; the future or too expensive for global use?
4.4.1 Major Side effects of Targeted Therapy
4.5 Immunotherapy (Biologic Therapy) - Great potential for some cancers, but lacking the wide range of other treatments?
4.5.1 Major Side effects of Immunotherapy
4.6 Hormonal Therapy
4.6.1 Major Side effects of Hormone Therapy
4.7.1 Major Side effects of Hyperthermia
4.8 Stem Cell Transplant
4.8.1 Major Side effects of Stem Cell Transplant
4.9 Other Therapies
4.9.1 Photodynamic Therapy
4.9.2 Side effects of Photodynamic Therapy
4.9.3 Laser Treatment
4.9.4 Side effects of Laser Treatment
Chapter 5 Cancer Therapies / Drugs Market Forecast
5.1 Global Targeted Therapy Market 2013 -2023
5.1.1 Rituxan/MabThera by Roche - Rituxan faces the end of patent exclusivity in key areas across our forecast period; how greatly will this effect global revenue?
5.1.2 Herceptin (Trastuzumab) by Roche - How will biosimilars affect Herceptin's bottom line in the near to mid future?
5.1.3 Avastin (Bevacizumab) by Roche - What potential does Avastin have to enter the combination therapies market in the US/European markets?
5.1.4 Gleevec (imatinib) by Novartis - Gleeva generated $4.7bn across 2012, how will this figure fair to 2023
5.1.5 Velcade (Bortezomib) by Takeda (Millennium) and J&J - GMR Data forecast negative growth for Velcade to 2023, how & why?
5.1.6 Tarceva (Erlotinib) by Roche - GMR Data forecast strong growth to 2018, which factors contribute to this forecast?
5.1.7 Sutent (Sunitinib) by Pfizer - Sutent revenue increased by 4% between 2011 and 2012, find out why here.
5.1.8 Sprycel (dasatinib) by Bristol Myers Squibb Sprycel's non-US sales revenue increased by 22% bewtween 2011 & 2012 ; find out which regions have driven this growth.
5.1.9 Nexavar (Sorafenib) by Bayer and Onyx - How hard will the (expected) loss of patent exclusivity hit Nexavar's bottom line across our forecast period?
5.1.10 Tasigna (Nilotinib) by Novartis - Tasigna is forecast to show strong growth throughout the forecast period - how & why?
5.1.11 Afinitor / Votubia (Everolimus) by Novartis
5.1.12 Xgeva (Denosumab) by Amgen
5.1.13 Yervoy (ipilimumab) by Bristol-Myers Squibb
5.1.14 Erbitux (cetuximab) by Bristol-Myers Squibb
5.2 Global Chemotherapy Market 2013 -2023
5.2.1 Alimta (Pemetrexed) by Eli Lilly
5.2.2 Xeloda (capecitabine) by Roche
5.2.3 Eloxatin (oxaliplatin) by Sanofi-Aventis
5.2.4 Temodar / Temodal (temozolomide) by Merck & Co.
5.2.5 Vidaza (azacitidine) by Celgene
5.2.6 Taxotere (docetaxel) by Sanofi-Aventis
5.2.7 Treanda (bendamustine hydrochloride) by Teva Pharmaceuticals
5.3 Global Immunotherapy (Biological therapy) Market 2013 -2023
5.3.1 Revlimid (lenalidomide) by Celgene
5.3.2 Gardasil (Human Papillomavirus Quadrivalent) by Merck
5.3.3 Zometa (zoledronate) by Novartis
5.4 Global Hormone Therapy Market 2013 -2023
5.4.1 Faslodex (Fulvestrant) Injection by AstraZeneca
5.4.2 Zoladex (Goserelin acetate implant) by AstraZeneca
5.4.3 Arimidex (anastrozole) by AstraZeneca
5.4.4 Casodex (bicalutamide) by AstraZeneca
5.4.5 Sandostatin (octreotide acetate) by Novartis
Chapter 6 Cancer R&D Pipeline and Drugs
6.1 R&D Pipeline
6.1.1 Oncology Drugs; Recent Approvals
6.1.2 Late Stage Cancer Drugs
6.1.3 Key Experimental Cancer Drugs Pipeline
6.1.4 Oncology Drug Pipeline Cancer Drugs Failures
Chapter 7 Major Trends & Challenges in the Global Cancer Drugs Market
7.1 Major Trends
7.1.1 Personalised Medication
7.1.2 Increasing Cancer Threat In Low & Middle Income Countries
7.1.3 Antibody Drug Conjugates (ADC)
7.1.4 Combination Therapy
7.1.5 Key Collaborations and Alliances
7.1.6 New Drug Development
7.1.7 Immunotherapy to be the next Industry Driver
7.2 Major Challenges
7.2.1 Expensive Treatment
7.2.2 Biosimilars Competition
7.2.3 Generic Competition
7.2.4 Severe Side Effects of Cancer Care Treatment
7.2.5 Regulatory Hurdles in Cancer Drug Approvals
Chapter 8 Regional Landscape The Key Global Cancer Drug Markets
8.1. The US Oncology Market to 2023
8.2. The UK Oncology Market to 2023
8.3. France Oncology Market to 2023
8.4 The German Oncology Market to 2023
8.5 The Spanish Oncology Market to 2023
8.6 The Italian Oncology Market to 2023
8.7 The Japanese Oncology Market to 2023
8.8 The Rest of the World Oncology Market to 2023
Chapter 9 Major Players in the Oncology Market
9.2 Ariad Pharmaceutical
9.3 ASTELLAS PHARMA
9.5 Bayer healthcare pharmaceuticals
9.6 Boehringer Ingelheim
9.7 Bristol-Myers Squibb
9.9 Eisai Co., Ltd.
9.10 Eli Lilly & Co
9.11 ImClone Systems Inc. (a subsidiary of Eli Lilly & Co)
9.14 Merck & Co
9.15 Millennium Pharmaceuticals (Subsidiary of Takeda Oncology Company)
9.16 Novartis Pharmaceuticals
9.17 Onyx Pharmaceuticals
9.18 Pfizer Inc.
9.21 Teva Pharmaceuticals Industries
Chapter 10 Expert Opinion
10.1 Dr John Marshall, Clinical Director of Oncology, Georgetown University Hospital
10.2 Dr Anderson Ryan, Senior Group Leader at Gray Institute of Radiation, Oncology and Biology, at the University of Oxford
10.3 Dr Ben Anderson, Professor of Surgery at the University of Washington & Chair of the Breast Health Global Initiative
Inquiry For Buying
COVID-19 Pandemic Impacts
Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.
Medical QMS Software-United States Market Status and Trend Report 2020-2025
Medical QMS Software-India Market Status and Trend Report 2020-2025
Medical QMS Software-China Market Status and Trend Report 2020-2025
Medical QMS Software-Asia Pacific Market Status and Trend Report 2020-2025
Medical QMS Software-EMEA Market Status and Trend Report 2020-2025View More
Along with 7 Realme Products, Realme Buds Q TWS Earbuds Will Also be Launched on May 25
Realme has added an addition in its product portfolio, i.e., the completely wireless headset Realm
iOS 13.5 and iPaDOS 13.5 Released by Apple Includes Features Relevant with COVID-19
Apple released its iOS 13.5 and iPadOS 13.5 that includes features that are appropriate for post-C
Canada and the US will no Longer Find Talc-based Johnson & Johnson Baby Powder
On Tuesday, Johnson Johnson made an official announcement that talc-based Johnsons Baby Powder wi
Foreign Investments being pulled out from Asian Countries
The world is facing one of deadliest recession of all times and amidst all these the foreign inves
Claims from the British American Tobacco that Coronavirus Vaccine Prepared by them is Ready for Human Trials
Every other region and institutions are trying out their level hard to find vaccination for COVID-